Liver transplant and recurrent disease

Area of Science:

• Hepatology
• Immunology
• Pharmacology

Background:

• Hepatitis B virus (HBV) recurrence post-liver transplantation (LT) poses a significant clinical challenge.
• Hepatitis B immune globulin (HBIG) is a cornerstone of prophylaxis, though dosing and target levels vary.
• Nucleoside/nucleotide analogs are used as adjuvant therapies but face challenges with drug-resistant HBV strains.

Purpose of the Study:

• To review current prophylactic strategies for preventing hepatitis B recurrence after liver transplantation.
• To discuss the evolving role of nucleoside/nucleotide analogs in managing post-LT HBV.
• To highlight the importance of HBIG and emerging therapeutic options.

Main Methods:

• Literature review of current prophylactic measures for HBV recurrence post-LT.
• Analysis of the efficacy and limitations of HBIG and nucleoside/nucleotide analogs.
• Discussion of evolving treatment paradigms and future therapeutic directions.

Main Results:

• Prophylactic measures, particularly HBIG, have significantly reduced HBV recurrence rates post-LT.
• Adjuvant nucleoside/nucleotide analog monotherapy is limited by drug resistance.
• Lamivudine with HBIG is effective if resistance has not developed, especially pre-LT.
• Adefovir is a preferred pre-LT option to enable post-LT lamivudine use.

Conclusions:

• HBIG remains essential for preventing HBV recurrence post-LT.
• The growing armamentarium of nucleoside/nucleotide analogs will further evolve post-LT HBV management.
• Future research may explore combination nucleoside analog therapies to combat resistance and optimize viral suppression.